KRAKOW, Poland, March 8,
2022 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a
clinical-stage drug discovery and development company focusing on
novel small molecule therapies that address emerging targets in
oncology, announced today that the data from its oncology programs
will be presented at the upcoming American Association of Cancer
Research (AACR) Annual Meeting 2022, taking place April 8-13 in New
Orleans, U.S.
Posters to be presented at the conference will include data from
RVU120, a CDK8/CDK19 inhibitor program targeting hematologic and
solid tumors, and data from an MTA-cooperative PRMT5 inhibitor
program.
"We are excited to share the recent preclinical data in breast
cancer from our most advanced oncology program, RVU120. This
selective inhibitor of CDK8/CDK19 is currently in Phase
1b clinical development for the
treatment of acute myeloid leukemia or high-risk myelodysplastic
syndromes, as well as in patients with metastatic or advanced solid
tumors, and has already delivered promising data," said Krzysztof
Brzózka, Chief Scientific Officer at Ryvu Therapeutics. "We have
also made rapid progress in our MTA-cooperative PRMT5 inhibitor
program, and we look forward to sharing these updates with the
scientific community," adds Dr. Brzózka.
Abstract/Poster Details:
Title: RVU120, a selective CDK8/CDK19 inhibitor,
demonstrates efficacy against hormone-independent breast cancer
cells in vitro and in vivo
Abstract Number: 2647
RVU120 is a specific, low nM, selective inhibitor of CDK8/CDK19,
currently being tested in a first-in-human Phase Ib clinical trial
in patients with metastatic or advanced solid tumors progressing
from previous lines of therapy (ClinicalTrials.gov: NCT05052255).
Studies on a panel of cell lines representing various subtypes of
breast cancer revealed that TNBC cells were highly sensitive to
RVU120. Molecular profiling of responder cells indicated high
enrichment for mesenchymal stem cells-like subtype. Single agent
efficacy of RVU120 has been confirmed in subcutaneous TNBC
xenograft models in vivo at well tolerated doses. Overall,
these studies provide rationale for further development of RVU120
in TNBC patients.
Session Title: Novel Targets and Pathways
Session Date and Time: Tuesday Apr
12, 2022 9:00 AM - 12:30
PM
Location: Poster Section 24
Title: Discovery of novel MTA-cooperative PRMT5
inhibitors as a targeted therapeutic for MTAP deleted cancers
Abstract Number: 1117
Targeting PRMT5 in MTAP-deleted tumors in a synthetic lethal
approach represents a promising antitumor strategy across many
tumor types. Ryvu has identified a series of MTA-cooperative PRMT5
inhibitors with good drug-like physicochemical properties and block
methyltransferase activity with nanomolar IC50 values. Ryvu
compounds selectively inhibit the growth of MTAP deleted cancer
cells in prolonged 3D culture, which strongly correlates with
inhibition of PRMT5-dependent protein symmetric demethylation
(SDMA) in those cells. Overall, these studies provide the
rationale for the further optimization of chemical series towards a
clinical candidate.
Session Title: Drug Targets
Session Date and Time: Monday Apr 11,
2022 1:30 PM - 5:00 PM
Location: Poster Section 23
Title: Trials in Progress – RVU120 SOL-021: An
open-label, single agent, Phase I/II trial of RVU120 (SEL120) in
patients with relapsed/refractory metastatic or advanced solid
tumors
Abstract Number: 8023
SOL-021 is a Phase I/II clinical
trial of RVU120 in patients with metastatic or advanced solid
tumors, who have exhausted available treatments, currently ongoing
in Poland and Spain (NCT05052255). The study is designed in
2 parts: Part 1 follows a 3+3 dose escalation design, and the
primary objectives are to characterize the safety and tolerability
of RVU120 as a single agent in patients with different tumors types
and determine the RP2D. Part 2 will primarily explore the
anti-tumor activity of RVU120 as a single agent in different
patient populations. As of a data cutoff of 11 Feb 2022, 5 patients have been enrolled in
Part 1 of the study and no DLTs have been observed.
This Trials in Progress abstract is published in cooperation with
the Early Clinical Trials Centre and Department of Oncology and
Radiotherapy, Medical University of Gdansk, Poland; Early Drug Development Unit (UITM)
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron
University Hospital, Barcelona,
Spain; Dep. of Internal Medicine III, Univ. Clinic, Bonn,
Germany and Maria Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Warsaw,
Poland.
Session Title: Phase II Trials in Progress
Session Date and Time: Monday Apr 11,
2022 9:00 PM - 12:30 PM
Location: Poster Section 34
About AACR Annual Meeting
The AACR Annual Meeting program covers the latest discoveries
across the spectrum of cancer research—from population science and
prevention, to cancer biology, translational, and clinical studies;
to survivorship and advocacy—and highlights the work of the best
minds in research and medicine from institutions all over the
world. Additional information is available on the AACR conference
website http://www.aacr.org.
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and
development company focused on novel small molecule therapies that
address emerging targets in oncology. Internally discovered
pipeline candidates make use of diverse therapeutic mechanisms
driven by emerging knowledge of cancer biology, including small
molecules directed at kinase, synthetic lethality, and
immuno-oncology targets. Ryvu's most advanced programs are: RVU120
- a selective CDK8/CDK19 kinase inhibitor with potential for the
treatment of hematological malignancies and solid tumors currently
in Phase I clinical development for the treatment of acute myeloid
leukemia and myelodysplastic syndrome, and Phase I/II for the
treatment of r/r metastatic or advanced solid tumors and SEL24
(MEN1703) - dual PIM/FLT3 kinase inhibitor licensed to the Menarini
Group, currently in Phase II clinical studies in acute myeloid
leukemia.
The Company was founded in 2007, and is headquartered in
Krakow, Poland. Ryvu is listed on the main market of
the Warsaw Stock Exchange, and is a component of sWIG80 index. For
more information, please see www.ryvu.com.
View original
content:https://www.prnewswire.com/news-releases/ryvu-therapeutics-to-present-data-from-its-oncology-programs-at-aacr-2022-annual-meeting-301498207.html
SOURCE Ryvu Therapeutics
